Revenue: As of FY2025, the actual value is USD 130 K.EPS: As of FY2025, the actual value is USD -1.91, beating the estimate of USD -2.08.EBIT: As of FY2025, the actual value is USD -23.81 M.<h4>Overview of Financial Performance</h4>Serina Therapeutics, Inc. had an accumulated deficit of - $63.5 million as of December 31, 2025.<h4>Revenue</h4><ul><li>Grant Revenues: Grant revenues were $130 thousand for the year ended December 31, 2025, an increase from $56 thousand for the same period in 2024.</li></ul><h4>Operating Expenses</h4><ul><li>Research and Development: Research and development expenses were $13.2 million for the year ended December 31, 2025, up from $7.5 million in 2024, representing a $5.7 million increase.</li><li>General and Administrative: General and administrative expenses were $11.0 million for the year ended December 31, 2025, compared to $9.6 million in 2024, reflecting a $1.4 million increase.</li><li>Total Operating Expenses: Total operating expenses were $24.152 million for 2025, an increase from $17.104 million for 2024.</li></ul><h4>Net Loss and Other Income/Expense</h4><ul><li>Operating Loss: The operating loss was - $24.0 million for 2025, compared to - $17.0 million for 2024.</li><li>Net Loss: The net loss was - $19.2 million for 2025, compared to - $11.2 million for 2024.</li><li>Total Other Income, Net: Total other income, net, was $4.8 million for 2025, a decrease from $5.8 million in 2024.<ul><li>Interest Expense: Interest expense was - $213 thousand in 2025, compared to - $526 thousand in 2024.</li><li>Change in fair value of convertible promissory notes: The change in fair value of convertible promissory notes was $0 in 2025, compared to - $7.017 million in 2024.</li><li>Change in fair value of warrants liabilities: The change in fair value of warrants liabilities was $4.263 million in 2025, compared to $13.156 million in 2024.</li><li>Gain on warrants expiration: Gain on warrants expiration was $724 thousand in 2025, compared to $0 in 2024.</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Net Cash Used in Operating Activities: Net cash used in operating activities was - $18.0 million in 2025, compared to - $17.1 million in 2024.</li><li>Net Cash Used in Investing Activities: Net cash used in investing activities was immaterial for both 2025 and 2024.</li><li>Net Cash Provided by Financing Activities: Net cash provided by financing activities was $17.4 million in 2025, compared to $13.2 million in 2024.</li></ul><h4>Liquidity</h4><ul><li>Cash and Cash Equivalents: Cash and cash equivalents were $3.1 million as of December 31, 2025.</li><li>Accumulated Deficit: The accumulated deficit was - $63.5 million as of December 31, 2025.</li></ul><h4>Outlook</h4>Serina Therapeutics, Inc. anticipates continued operating losses and increased expenses for research and development, general and administrative, and capital expenditures as it advances its product candidates. The company’s current cash is not expected to fund operations for at least twelve months, necessitating additional financing through equity, debt, or collaborations. Failure to secure this capital could lead to delays, curtailment, or termination of planned activities, impacting the company’s ability to continue as a going concern.

Serina Therapeutics | 10-K: FY2025 Revenue: USD 130 K